$MLTX

Analysts made several rating changes: Seaport upgraded SiTime (SITM) to Buy with a $425 target, citing AI cycle potential. Wells Fargo upgraded Becton Dickinson (BDX) to Overweight with a $242 target, expecting improved growth. Roth upgraded Centrus Energy (LEU) to Buy with a $115 target, noting acquisition benefits. JPMorgan upgraded SQM (SQM) to Overweight with a $71 target, seeing valuation support.

Chardan initiated coverage on Moonlake Immunotherapeutics (NASDAQ:MLTX) with a buy rating and $57 price target, citing potential in its HS drug. The stock trades at $10.80. The FDA has aligned on the efficacy package for sonelokimab, with approval anticipated in Q3 2027. Chardan assigns an 85% probability of approval. Cantor Fitzgerald reiterated an Overweight rating on MLTX.

MoonLake reported a Q3 2026 net loss of $79.5M, with $498.5M in cash. R&D expenses rose to $68.9M due to BLA submission costs. The company expects cash runway to mid-2028. It submitted a BLA for sonelokimab and reported positive trial results.

MoonLake Immunotherapeutics (MLTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update • Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, ma

MoonLake Immunotherapeutics (MLTX) shares rose 18% after AbbVie (ABBV) reported Phase 3 trial results for a competing hidradenitis suppurativa drug. AbbVie's lutikizumab showed an 8-point improvement over placebo, which RBC Capital deemed underwhelming. MoonLake's sonelokimab previously demonstrated a 14-point improvement in a similar trial. MoonLake awaits FDA review of its drug application, submitted on Sept. 30, with a potential US launch in late 2027.

MoonLake Immunotherapeutics (MLTX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the treatment of moderate-

U.S. stock futures fell Sunday night after President Trump rejected Iran's peace proposal, raising concerns about global energy supplies. Dow, S&P 500, and Nasdaq futures declined, while oil prices rose. Micron (MU) and Sandisk (SNDK) shares surged over 5% due to high demand for memory chips. Everspin (MRAM) and MoonLake (MLTX) also saw significant gains.

U.S. stock futures fell early Monday due to tariff uncertainty and Iran tensions. Nasdaq, S&P 500, and Dow futures declined 0.5%-0.6%. Nvidia's earnings, Netflix's board controversy, and Honeywell's acquisition are in focus. Precious metals rose, with gold above $5,100 and silver near $88/oz.

MoonLake Immunotherapeutics (MLTX) shares surged 11% after Cormorant Asset Management increased its stake to 6.1%. The FDA granted Fast Track designation to Sonelokimab, and retail traders speculate a potential takeover. MLTX is up 33% YTD, with an investor day scheduled for Feb. 23.

MoonLake Immunotherapeutics (MLTX) shares rose 2.5% as investors anticipate late-stage trial results for its lead drug, sonelokimab, focusing on hidradenitis suppurativa. Full 52-week data is expected in Q2, with FDA submission planned for September 2026. Analysts' average price target is $27.62, implying 46% upside. MLTX stock has gained 63% this year, with retail sentiment turning bullish.